Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …

Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both
angiogenic pathways (ie, vascular endothelial growth factor receptor and platelet-derived …

Abstract Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase
inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has …

Abstract Sunitinib maleate (Sutent; Pfizer) is a small-molecule inhibitor of multiple receptor
tyrosine kinases involved in cancer, including vascular endothelial growth factor receptors …

Sunitinib is an orally available small-molecule multikinase inhibitor. This agent potently
inhibits the vascular endothelial growth factor receptor, platelet-derived growth factor …

Sunitinib is a small-molecule inhibitor of several receptor tyrosine kinases relevant to tumor
angiogenesis, including the vascular endothelial growth factor (VEGF) receptor. Potent …

Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain receptor
tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR …

Receptor tyrosine kinases (RTKs) play important roles in the regulation of cellular growth,
and mutated or overexpressed RTKs have been implicated in various human cancers …

Sunitinib (SU-11248, Sutent) inhibits at least eight receptor protein-tyrosine kinases
including vascular endothelial growth factor receptors 1–3 (VEGFR1–VEGFR3), platelet …

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …